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Abstract 
Review on NDRG1, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Identity 
Other names: CAP43, CMT4D, DRG-1, DRG1, 
GC4, HMSNL, NDR1, NMSL, PROXY1, RIT42, 
RTP, Rit42, TARG1, TDD5 
HGNC (Hugo) : NDRG1 
Location : 8q24.22 
Location (base pair) 
Start: 133,237,171 bp from pter End: 133,302,022 bp 
from pter (according to GRCh38/hg38 Dec_2013) 
DNA/RNA 
Description 
NDRG1 was mapped to human chromosome 8q24 
and consists of 64,851 basepairs, starting at basepair 
133,237,171 and ending at basepair 133,302,022 
from the p-terminus.  
It is a member of the NDRG family, consisting of 
NDRG1, NDRG2, NDRG3 and NDRG4 (of which 
three isoforms exist: NDRG-4B, NDRG-4Bvar and 
NDRG-4H), which are part of the alpha/beta 
hydrolase superfamily.  
The members of the NDRG family share 52-65% 
amino acid identity.  
The promoter region of all NDRG family members 
contain CpG islands (Bandyopadhyay et al., 2004). 
NDRG1 downregulation has been correlated with 
DNA hypermethylation in some types of human 
cancer and cell lineages such as prostate, breast and 
gastric and also in sclerosis-affected brains (Li et al 
, 2015; Huynh et al , 2014; Han et al , 2013; Chang 
et al , 2013). 
Transcription 
The DNA of NDRG1 contains 16 exons, see diagram 
for details about their location.  
The DNA encodes a 3.0 kb mRNA with a coding 
region of 1.185 kb. 
DNA size: 64.85Kb; mRNA size: 3123 bp (NM_006096.3); 16 exons. 
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Protein 
Note 
Molecular weight: 42,835 KDa, 394aa 
(NP_001128714.1) 
Description 
NDRG1 is a ~ 43 kD protein, composed of 394 
amino acids, with an iso-electric point of 5.7. 
NDRG1 has an alpha/beta hydrolase-fold motif, 
however, without a hydrolytic catalytic activity 
required to function as hydrolases. The protein has 
no apparent transmembrane domain (Kokame et al, 
1996). NDRG1 has several phosphorylation sites, 
among others a phosphopantetheine attachment site, 
protein kinase C, casein kinase II, tyrosine kinase, 
protein kinase A and calmodulin kinase II. 
Experimental studies have demonstrated that 
NRDG1 is phosphorylated by Protein Kinase A and 
Calmodulin kinase II, and is also a physiological 
substrate of SGK1 and GSK-3-beta kinase (Figure 
1), a kinase involved in cancer growth and 
progression. he C-terminal region of NDRG1 
(residues 339-369) possess three tandem repeats of 
10 amino acids, GTRSRSHTSE, (Zhou et al, 2001) 
not present in the other members of the NDRG 
family. These repeats with a histidine located 
between serine and threonine residues act as a 
binding site for metal ions such as nickel and copper 
(Zoroddu et al, 2001) (Figure 1). NDRG1 is also 
target for SOMOylation, preferentially by SUMO-2 
isoform, in an acceptor site in residue Lys14. This 
modification does not affect the subcellular 
localization of NDRG1 but the protein stability by 
increasing protein ubiquitination and degradation 
(Lee and Kim, 2015) (Figure 1). 
Expression 
NDRG1 is relatively ubiquitously expressed in 
normal human cells, and especially highly expressed 
in prostate, brain, kidney, placenta, ovarian, thyroid, 
testicular and intestinal cells. NDRG1 is mostly 
found in epithelial cells. NDRG1 expression has 
been shown to be controlled by promoter CpG island 
methylation and histone acetylation. In addition, 
several transcription factors have been implicated in 
the NDRG1 transcriptional regulation, including 
homo- and heterodimers of MYC, MYCN and 
MAX, androgen receptor (AR), TP53, and HIF1A. 
Localisation 
NDRG1 is primarily a cytoplasmic protein. 47.8% of 
the NDRG1 is expressed in the cytosol, 26.1% in the 
nucleus (such as in prostate epithelial cells), and 
8.7% in the mitochondria (such as in proximal tubule 
cells in the kidney).  
NDRG1 is also found in the adherens junctions. 
Additionally, in intestinal and lactating breast 
epithelia NDRG1 is located in the plasma 
membrane. NDRG1 can also be found in vacuoles, 
the peroxisome, early and recycling endosomes, and 
the cytoskeleton. 
Function 
The exact function of NDRG1 is still unclear. The 
expression of all members of the NDRG1 family has 
been correlated with different stages of 
differentiation from birth to adulthood. NDRG1 has 
been reported to be involved in different biological 
processes as cell proliferation, differentiation, 
development, and stress response (Ellen et al., 2008). 
There is evidence that NDRG1 expression peaks in 
the G1 and G2/M phases, and is lowest in the S 
phase, and that this regulation might be associated to 
cell growth and differentiation. In fact, NDRG1 has 
been shown to up regulates p21/WAF1 (Kovacevic 
et al, 2013) and NDRG1 expression is 
downregulated under conditions of increased cell 
proliferation. NDRG1 is also described as a 
microtubule-associated protein, which may play an 
important role in maintaining spindle structure 
during cell division. 
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 Figure 1 - Schematic representation of the modular structure of NDRG1 - NDRG1 is target of phosphorylation by PKA, 
PKC, CaMKII. Residues that are phosphorylated by SGK1 and GSK3 and target of SUMOylation by SUMO-2 are indicated. PKA: 
Protein Kinase A; PKC: Protein Kinase C; CaMKII: Calmodulin Kinase II; SGK1: serum and glucocorticoid-regulated kinase 1; 
GSK3- Glycogen synthase kinase 3; SUMO-2: Small Ubiquitin-Like Modifier 2 . 
 
The function of NDRG1 may be controlled at least 
in part by phosphorylation. Phosphorylation at 
residues Ser330 and Thr346 by SGK-1 is involved in 
NF-κB signaling pathway inhibition probably 
affecting cell survival (Murakami et al, 2010). 
NDRG1 has also been identified as a stress response 
gene, upregulated by homocysteine and hypoxia. 
Hif-1-dependent and independent mechanisms have 
been implicated in NDRG1 induction. It is also 
controlled by AP-1 transcription factors. When 
exposed to stress, for example hypoxia, NDRG1 
may play a cytoprotective role in normal healthy 
cells. 
NDRG1 is upregulated during colon epithelial cell 
differentiation. It is positively or negatively 
regulated by hormones such as androgens and 
estradiol, respectively. Small molecules such as N-
hydroxy-N'-phenol-octane-1,8-diotic acid diamide, 
calcium ionophores like BAPTA, metal ions such as 
Nickel and Cobalt, iron chelators and differentiating 
agents like retinoic acid induce NDRG1 expression. 
Additionally, NDRG1 is induced during cellular 
DNA damage and endoplasmic reticulum stress. 
In the Schwann cells, NDRG1 is essential for myelin 
sheath maintenance. Hence, NDRG1 is a 
multifunctional protein with roles that may be tissue- 
and/or cell-type specific. 
It has been found to be a Rab4a effector protein that 
recruits to the recycling endosomes in the Trans 
Golgi network by binding to the lipid 
phosphotidylinositol 4-phosphate (PI4P), where it 
plays a role in the recycling of E-cadherin. NDRG1 
also interacts with HSP70. NDRG1 co-localizes with 
APO A-I and A-II, and may be involved in lipid 
transport. 
Evidences obtained from global gene expression 
analysis of breast cell lines with high endogenous 
NDRG1 expression transduced with shRNA against 
NDRG1 suggested an involvement of NDRG1 with 
vesicle transport (Askautrud et al, 2014). 
In cancer, NDRG1 is reported to be a metastasis 
suppressor gene which is downregulated in prostate, 
colon and breast cancers.  
However, up-regulation of NDRG1 has also been 
associated to poor prognosis in breast, renal, 
hepatocellular, and colorectal cancer, suggesting that 
it may play different role depending on cellular type 
and context (Nagai. et al, 2001; Nishie et al, 2001; 
Chua et al, 2007; Strzelczyk et al, 2009). 
Signaling Pathways 
The widespread localization of NDRG1 might 
impact its involvement with diverse signaling 
pathways. It has been demonstrated that NDRG1 
interacts directly with NF-κB, PI3K/AKT/ mTOR, 
Ras/Raf/MEK/ERK, TGF-β; and Wnt/β-catenin 
pathways independently with each pathway or by 
promoting a crosstalk between them (Sun J et al, 
2013).  
The nuclear translocation of the DNA binding 
subunit of NFκB, NFKB1 (p50), complexed with 
RelA is reduced by NDRG1 as a consequence of the 
induced degradation of IKBKB (IKK&beta), subunit 
of the IκB kinase complex (Hosoi et al, 2009). The 
effect of NDRG1 on NFκB signaling pathway seems 
to be dependent of phosphorylation at residues 
Ser330 and Thr346 by SGK1 (Murakami et al, 
2010). 
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 Figure 2 - Modulators and Biological functions of NDRG1 - NDRG1 is involved in a variety of signaling pathways been 
positively or negatively regulated. As a consequence, diverse biological processes are modulated. HIF1, hypoxia inducible factor 
1; c-Myc, v-myc avian myelocytomatosis viral oncogene homolog; AR, Androgen receptor; E2, -17β-estradiol; AP1, activator 
protein-1, p53, tumor suppressor protein p53; PTEN, phosphatase and tensin homolog; VEGF, vascular endothelial growth 
factor; CXCL8 (IL-8), interleukin-8; p21, cyclin-dependent kinase inhibitor 1A; NFKB, nuclear factor of kappa light polypeptide 
gene enhancer in B-cells; pERK, extracellular signal-regulated kinases; SMAD4, SMAD family member 4; PI3K, 
phosphatidylinositol 3-kinase; AKT, v-akt murine thymoma viral oncogene homolog. 
 
The expression of PTEN, a tumor suppressor gene 
described as inactivated in diverse types of human 
cancers, is also involved in tumor metastasis 
suppression and it was demonstrated that PTEN 
targets NDRG1 in a PI3K dependent manner. It was 
demonstrated that up regulation of PTEN increase 
the level of NDRG1 and the inhibition of PTEN by 
shRNA also inhibits NDRG1 expression. This 
blockage is reverted when the cells are treated with 
phospho-Akt inhibitor, evidencing a dependency of 
PI3K/AKT pathway (Bandyopadhyay, et al, 2004). 
In prostate epithelial cells NDRG1 expression 
increased phosphorylation of tumorigenic AKT, 
ERK1/2 and SMAD2L and decreased PTEN levels 
(Dixon et al, 2013). NDRG1 also has been associated 
to up-regulation of SMAD4 that is responsible for 
nuclear translocation of effector SMADs upon TGFβ 
receptor activation. Up regulation of SMAD4 has a 
dual role both in TGFβ signaling, intermediating the 
induction of p21, and also blocking Ras signaling 
pathway by inhibiting ERK phosphorylation 
(Kovacevic et al, 2013) (Figure 2). 
Homology 
NDRG1 amino acid sequence is 53% homologous to 
NDRG2, 62% to NDRG3, 62% to NDRG4, and 94% 
homologous to the mouse analog, Ndr-1 (also known 
as TDD5). NDRG1 homologs have been found in 
Helianthus, Caenorhabditis, Xenopus and 
Drosophilia. 
Implicated in 
Prostatic adenocarcinoma, breast 
cancer, colorectal cancer, renal cell 
carcinoma, bladder carcinoma, 
pancreatic cancer, hepatocellular 
carcinoma, thyroid carcinoma, and 
glioma. 
Prognosis 
The association of NDRG1 and prognosis of cancer 
patients is controversial.  Some studies have found 
that downregulation of NDRG1 in cancer worsens 
the prognosis of cancer. There is an inverse 
relationship in the levels of NDRG1 expression and 
the Gleason grade of the tumor in prostate cancer. A 
high PTEN (a tumor suppressor which positively 
regulates NDRG1) and NDRG1 expression 
improves survival rates in patients with breast and 
prostate cancer. In patients with colorectal cancer, 
the 2 year survival rate for patients with high 
NDRG1-expression was 82.4%, while for patients 
with a low NDRG1-expression it was only 69.6%. In 
pancreatic cancer patients, the median survival time 
for patients with high NDRG1-expression was 24.7 
months, while the median survival time for patients 
with low NDRG1-expression was only 10.9 months. 
High expression of NDRG1 in colon tumors was 
found to correlate with increased resistance to 
irinotecan.  
On the other hand, the positivity for NDRG1 
expression was associated to poor disease free and 
overall survival of breast cancer patients. Also, the 
positivity of NDRG1 protein observed in breast 
NDRG1 (N-myc downstream regulated 1) Nagai MA, Mangone FR 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(7) 417 
 
cancer patients is associated with important clinic-
pathological variables for disease outcome, such as 
large tumor size, advanced clinical stage, lymph 
node metastasis and high tumor grade (SBR) (Nagai. 
et al, 2001). An inverse correlation of NDGR1 and 
ER and/or PR status has also been described (Leth-
Larsen et al, 2009; Fotovati et al, 2006).  
Increase in protein level has been observed in thyroid 
carcinomas.  Thyroid lesions showed higher 
immunohistochemical staining of NDRG1 as 
compared to normal and benign thyroid lesions that 
was correlated with more advanced tumor stages. 
This increase of NDRG1 expression was correlated 
with more advanced TNM stage (stages III and IV) 
and an AMES high-risk category in patients with 
thyroid carcinoma (Gerhard et al, 2010).  
In hepatocellular carcinoma upregulation of NDRG1 
has been correlated with tumour aggressiveness and 
poor patients' survival (Chua et al., 2007).  
NDRG1 has been associated to breast cancer cells 
differentiation both in vitro and in vivo. Endogenous 
expression of NDRG1 was associated to 
differentiation status of breast cancer cell lines and 
when these cells were treated with the cellular 
differentiation inducer, sodium butyrate, a 
concomitant increase of NDRG1 and β-casein, a 
marker of breast cell differentiation, expression was 
observed. Moreover, the blockage of NDRG1 
expression was also followed by β-casein reduction. 
Also in breast cancer samples a close relationship 
between NDRG1 and β-casein was found (Fotovati  
et al, 2011).  
NDRG1 has been considered as a possible biomarker 
to guide the decision of treatment of WHO grade II 
glioma patients. Time to reintervention, assessed for 
patients without immediate postoperative genotoxic 
treatment and known progression and survival 
status, was significantly longer in the high NDRG1 
group. This group of tumors presented growth delay 
improving progression free surviva (Blaes et al, 
2014).  
Oncogenesis 
NDRG1 aberrant expression has been reported in 
different types of cancer, indication that it plays an 
important role in the tumorigenic process. However, 
both tumor suppressive and oncogenic functions 
have been demonstrated for NDRG1, suggesting an 
impact of its tissue specific function.  
An inverse relationship exists between NDRG1 and 
the oncogenes N-myc and c-myc, suggesting that 
members of the MYC family suppress expression of 
NDRG1. Experimental evidence exist that both N-
myc and c-myc downregulate NDRG1 gene 
expression by directly binding to NDRG1 promoter. 
NDRG1 is downregulated in colon, breast, prostate 
and pancreatic neoplasms, by c-myc and N-myc 
transcription factors. In cancer cells, NDRG1 
expression is consistent through all phases in the cell 
cycle, instead of the biphasic expression in normal 
cells. PTEN expression is positively related to 
NDRG1 expression. NDRG1 is induced in cancer 
cells by histone deacetylase inhibitors and DNA 
methyl transferase inhibitors indicating that NDRG1 
is regulated by chromatin modulation and DNA 
methylation. 
Although NDRG1 has been reported to be 
downregulated in a variety of cancers, it has been 
shown to be upregulated in hepatic, pancreatic and 
kidney cancers. Induction of NDRG1 in these tumors 
is speculated to be in response to tumor stress or 
hypoxia and NDRG1 is proposed as a marker of 
tumor hypoxia. However, in pancreatic cancer, 
cellular differentiation and not hypoxia was 
demonstrated to be the determining factor for 
NDRG1 expression. In renal cancer, induction of 
NDRG1 in the tumor tissue was restricted to 
infiltrating macrophages and not cancer cells. 
NDRG1 is suggested to be an early target for p53. 
Loss of p53 expression in cancer is suggested to 
reduce NDRG1 expression. However, p53 knockout 
mice show expression of NDRG1, suggesting that 
there are other mechanisms regulating NDRG1 
levels. 
NDRG1 expression plays a role in vitro in primary 
tumor growth in prostate, breast, and bladder cancer: 
a higher expression of NDRG1 lowers the 
proliferation rates of these cancers. In pancreatic and 
bladder cancer cells, this reduction was proven in 
vivo: in pancreatic cells it was suggested that the 
reduced proliferation was caused by NDRG1 by 
modulating tumor stroma and angiogenesis. NDRG1 
can recruit onto the recycling endosome in the Trans-
Golgi network by binding to phosphotidylinositol 4-
phosphate. There, NDRG1 may be involved in the 
transport of various cargo back to the cells' surface. 
At the molecular level, NDRG1 may stabilize the E-
cadherin molecule by recycling it back to the cells' 
surface, thereby preventing tumor invasion. 
Hereditary Motor and Sensory 
Neuropathy-Lom (HMSNL) / Charcot-
Marie-Tooth Disease (CMT 4D) 
Note 
Autosomal recessive mutation in NDRG1 is 
responsible for HMSNL/CMT 4D inheritance. The 
Gypsy founder mutation, homozygote R148X, also 
called homozygote C564t is a causative mutation. In 
patients with CMT disease, apart from the R148X 
mutation, another disease-causing mutation was 
identified, namely IVS8-1G>A  (g.2290787G>A), 
which results in skipping of exon 9. The homozygote 
phenotype of this mutation was very closely related 
to the phenotype of HMSNL patients.  
An increased copy number (chr8: 134265065-
134271319) covering NDRG's1 exons 6-8 was 
detected in CMT individual. Heterozygous 
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individuals for the locus duplication are carriers for 
the disease while the homozygous are affected. Also, 
the presence of this duplication leads to a nonsense 
mutation at codon 223 affecting gene function 
(Okamoto et al, 2014). 
Disease 
A hereditary autosomal recessive disease, caused by 
demyelination of peripheral nerves. It is the most 
common form of demyelinating Charcot-Marie-
Tooth disease in the Roma population. 
Prognosis 
Severe disability in adulthood. It begins consistently 
in the first decade of life with a gait disorder, 
followed by upper limb weakness in the second 
decade and, in most subjects, by deafness setting in 
in the third decade of life. Sensory loss affecting all 
modalities is present; both this and the motor 
involvement predominating distally in the limbs. 
Skeletal deformity, particularly foot deformities, are 
frequent. 
Atherosclerosis 
Note 
Patients with HMSNL were found to have a high 
total cholesterol: HDL-C ratio. 
Disease 
Atherosclerosis is an important factor for the 
development of cardiovascular diseases, like 
myocardial infarction and angina pectoris. NDRG1 
contributes to HDL-C (high-density lipoprotein-
cholesterol) levels most likely by its 
phosphopantetheine-binding domain interacting 
with the high-density lipoproteins apolipoprotein A-
I and A-II 
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